KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quest Diagnostics (DGX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Quest Diagnostics (DGX) over the last 17 years, with Q3 2025 value amounting to $20.0 million.

  • Quest Diagnostics' Share-based Compensation rose 526.32% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $90.0 million, marking a year-over-year increase of 1250.0%. This contributed to the annual value of $88.0 million for FY2024, which is 1428.57% up from last year.
  • Latest data reveals that Quest Diagnostics reported Share-based Compensation of $20.0 million as of Q3 2025, which was up 526.32% from $21.0 million recorded in Q2 2025.
  • Over the past 5 years, Quest Diagnostics' Share-based Compensation peaked at $27.0 million during Q4 2024, and registered a low of $16.0 million during Q2 2023.
  • In the last 5 years, Quest Diagnostics' Share-based Compensation had a median value of $20.0 million in 2024 and averaged $20.2 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first crashed by 4411.76% in 2021, then soared by 4210.53% in 2024.
  • Quest Diagnostics' Share-based Compensation (Quarter) stood at $19.0 million in 2021, then grew by 15.79% to $22.0 million in 2022, then fell by 13.64% to $19.0 million in 2023, then surged by 42.11% to $27.0 million in 2024, then dropped by 25.93% to $20.0 million in 2025.
  • Its Share-based Compensation stands at $20.0 million for Q3 2025, versus $21.0 million for Q2 2025 and $22.0 million for Q1 2025.